Core Viewpoint - The company, Hehua Co., Ltd. (河化股份), is undergoing a potential change in its controlling shareholder, which may lead to a shift in actual control, as notified by its major shareholder, Ningbo Yinyi Holdings Co., Ltd. [1] Group 1: Shareholder Changes - Hehua Co., Ltd. has received a notification from its controlling shareholder regarding the planning of a share transfer, which may result in a change of control [1] - The company has applied for a trading suspension for its stock starting from July 31, 2025, to ensure fair information disclosure and protect investor interests [1] Group 2: Business Overview - Hehua Co., Ltd. primarily engages in the research, production, and sales of pharmaceutical intermediates and urea processing and sales [1] - The company’s subsidiary, Nansong Pharmaceutical, specializes in the development and production of pharmaceutical intermediates, with key products including anti-malarial, progestogen, and nutritional intermediates, serving both domestic and international markets [1] Group 3: Operational Strategy - The company has established a comprehensive operational framework, including R&D, production facilities, quality inspection centers, and sales departments to meet market demands [2] - Hehua Co., Ltd. plans to expand its product chain, enhance management efficiency, increase R&D investment, and strengthen market development for new products as part of its 2025 operational plan [2][3] Group 4: Financial Performance - In 2024, Hehua Co., Ltd. reported a revenue of 212 million yuan, reflecting a year-on-year growth of 12.81%, and a net profit of 79.25 million yuan, marking a significant increase of 785.62% [3] - In the first quarter of this year, the company achieved a revenue of 40.83 million yuan and a net profit of 1.36 million yuan, indicating a turnaround from previous losses [3]